75 studies found for:    myeloma AND (women OR woman OR female)
Show Display Options
Rank Status Study
21 Active, not recruiting S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Conditions: Breast Cancer;   Lung Cancer;   Metastatic Cancer;   Multiple Myeloma;   Plasma Cell Neoplasm;   Prostate Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Procedure: assessment of therapy complications
22 Recruiting ACE-011 With Lenalidomide+Dexamethasone for Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: ACE-011;   Drug: Lenalidomide;   Drug: Dexamethasone
23 Active, not recruiting Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma
Conditions: Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: dexamethasone;   Drug: lenalidomide;   Drug: bortezomib;   Other: laboratory biomarker analysis
24 Active, not recruiting Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement
Conditions: Breast Cancer;   Metastatic Cancer;   Multiple Myeloma and Plasma Cell Neoplasm;   Musculoskeletal Complications;   Pain;   Prostate Cancer;   Urinary Complications
Intervention: Drug: zoledronic acid
25 Recruiting Evaluating the Efficacy and Safety of the Lower Dose of Bortezomib Plus Busulfan and Melphalan as a Conditioning Regimen in Patients With Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation- KMM103 Study
Condition: Multiple Myeloma Patients Who Candidate for Autologous Peripheral Blood Stem Cell Transplantation
Intervention: Drug: Bortezomib
26 Active, not recruiting
Has Results
S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Biological: filgrastim;   Biological: sargramostim;   Drug: cyclophosphamide;   Drug: dexamethasone;   Drug: melphalan;   Drug: prednisone;   Drug: thalidomide;   Procedure: peripheral blood stem cell transplantation
27 Terminated Treatment of Malignant Vertebral Fractures With Percutaneous Balloon Kyphoplasty.
Conditions: Vertebral Fracture;   Multiple Myeloma;   Osteolytic Metastases
Intervention: Device: balloon kyphoplasty
28 Completed
Has Results
American Ginseng in Treating Patients With Fatigue Caused by Cancer
Conditions: Chronic Myeloproliferative Disorders;   Fatigue;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms;   Precancerous Condition;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: American ginseng;   Other: placebo
29 Completed ExAblate (Magnetic Resonance-guided Focused Ultrasound Surgery) Treatment of Metastatic Bone Tumors for the Palliation of Pain
Conditions: Bone Metastases;   Multiple Myeloma
Interventions: Device: ExAblate 2000;   Device: Sham
30 Completed A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Related Lymphoid Malignancies
Conditions: Lymphoma, Mantle-cell;   Leukemia, Lymphocytic, Chronic, B-Cell;   Leukemia, Hairy Cell;   Waldenstrom Macroglobulinemia;   Multiple Myeloma
Intervention: Drug: ON01910 Na
31 Recruiting Lenalidomide/Bortezomib/Dexamethasone for Multiple Myeloma (MM)
Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide;   Drug: Bortezomib;   Drug: Dexamethasone
32 Recruiting Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects With Multiple Myeloma and Renal Disease
Conditions: Relapsed Multiple Myeloma;   End-stage Renal Disease
Intervention: Drug: Carfilzomib
33 Recruiting Cytogenetic Studies in Acute Leukemia and Multiple Myeloma
Conditions: Acute Leukemia;   Acute Lymphoblastic Leukemia;   Myelodysplastic Syndrome;   Multiple Myeloma
Intervention: Genetic: cytogenetic analysis
34 Not yet recruiting Evaluation of the Safety and the Efficacy of Carfilzomib Combined With Cyclophosphamide and Dexamethasone (CCyd) or Lenalidomide and Dex (CRd) Followed by ASCT or 12 Cycles of Carf Combined With Dex and Len for Patients Eligible for ASCT With Newly Diagnosed Multiple Myeloma.
Condition: MULTIPLE MYELOMA (MM)
Interventions: Drug: Carfilzomib;   Drug: Cyclophosphamide;   Drug: Lenalidomide;   Drug: Dexamethasone
35 Active, not recruiting Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
Conditions: Ovarian Cancer;   Renal Cancer;   Non-small Cell Lung Cancer;   Small Cell Lung Cancer;   Solid Tumors;   Multiple Myeloma;   Lymphoma
Interventions: Drug: Carfilzomib 30 min IV infusion;   Drug: Carfilzomib bolus administration up to 10 min;   Drug: Carfizomib 30 min infusion plus 40 mg/week dexamethasone
36 Recruiting A Non-interventional,Observational Post Authorization Study of Patients With Multiple Myeloma Treated With Lenalidomide TR
Condition: Multiple Myeloma
Intervention:
37 Active, not recruiting Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma
Conditions: Refractory Multiple Myeloma;   Relapsed Multiple Myeloma;   Multiple Myeloma
Interventions: Drug: Bortezomib;   Drug: CC-5013
38 Active, not recruiting Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: bortezomib
39 Recruiting Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN 07LT)
Condition: Multiple Myeloma
Intervention: Drug: Lenalidomide
40 Active, not recruiting Blockade of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell Transplantation
Condition: Multiple Myeloma
Interventions: Drug: CT-011;   Biological: Dendritic Cell Fusion Vaccine

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years